Ģý

Contact

Career
Country websites

Attention

The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

The product related information on the websites covers Ģý unless explicitly stated otherwise Ģý only CE marked products which are marketable in the European Union. Please be aware that not all products and services described on the following website are cleared or available for sale in all countries.Please check the relevantcountry web sitefor details.

By clicking the button ĢýAccepted and ConfirmedĢý you assure that you have taken note of this information.

Back to Homepage Accepted and Confirmed

CiĢýCa therapy

Integrating CiĢýCa therapy in your clinical practice

CiĢýCa therapy is a continuous kidney replacement therapy method that was developed by Ģý together with experienced clinicians. It was designed to provide reliable regional anticoagulation, using machine integrated citrate and calcium management.

DISCLAIMER

Not all products and services are cleared or available for sale in all EU countries. Check yourcountry web sitefor details.

Think CiĢýCa therapy.
Your responsibility in good hands.

Your professional world is changing constantly. You appreciate technologies that are continuously evolving and help you to provide your patients with even better therapy. We would like to support you by offering a comprehensive approach for citrate anticoagulation-based CKRT: CiĢýCa therapy.

At a time when healthcare professionals are increasingly involved in non-caregiving activities such as administration, treatment documentation and medication preparation, there is a growing need for reliable, one-stop solutions which decrease the strain on the ICU staff.

Ģý is the first provider to offer a complete range of CiĢýCa therapy products from a single source, supporting healthcare professionals to focus on the essential: patient care.

Regional citrate anticoagulation enables patient treatment with less bleeding complications and less filter clotting compared to heparin CKRT.1Ģý3As one option to implement regional citrate anticoagulation, CiĢýCa therapy is an effective and reliable alternative to heparin4Ģý11and lets your ICU staff focus more on the patient and less on handling issues.5,11

Regional citrate anticoagulation in extracorporeal blood circuits

Watch to learn more

Participate in our experience: Ģý was the first to offer a completely machine integrated CiĢýCa regional citrate anticoagulation. Healthcare professionals in more than 30 countries have already gained experience with CiĢýCa therapy and appreciate its reliable and easy application in clinical routines.5,6

Our proven citrate protocol is fully integrated in themultiFiltratePROand reflected in all our CiĢýCa products.

Think reliable.
Think CiĢýCa therapy.

ICU days are busy and, as a doctor, you need to stay in control of a very complex environment. You shouldnĢýt need to worry about the reliability of CKRT treatments. We enable excellent patient treatment with few clotting and bleeding complications.5Ģý8,13,14

Your question

What is the advantage of CiĢýCa therapy over standard heparin treatment?

Our answer

Citrate anticoagulation-based CKRT enables excellent patient treatment with fewer bleeding complications and less filter clotting compared to heparin.3,12Ģý14CiĢýCa regional anticoagulation is an effective and reliable alternative to heparin:

  • Proven citrate protocol5Ģý8
  • Enabling adherence to KDIGO AKI guideline2
  • Low associated bleeding risk5,7,8
  • Long filter patency4,6,8,10

Think smart.
 Think CiĢýCa therapy.

Nurses carry a lot of responsibility. So you look for ways to reduce workload and to focus on what is important. We help you to conduct a smoothly running CKRT with few interventions, making your work more plannable and enabling you to focus more on your patient.5,11

Your question

How can CiĢýCa therapy give me more plannability and reduce my workload?

Our answer

Compared to heparin anticoagulation, CiĢýCa therapy reduces the number of nurse interventions, and facilitates efficient work planning:

  • Prolonged filter lifetime corresponds to fewer filter changes4,10
  • Low bleeding risk with expectedly fewer interventions needed5,7,8
  • CiĢýCa Therapy protocol and products support a predictable workflow5,11


Think valueĢýbased.
 Think CiĢýCa therapy.

Budget decisions come with a lot of responsibility. You want to make sure that your clinic is offering the best possible treatment while managing your budget wisely. We strive to limit total cost of ownership while conducting advanced therapies.

Your question

How does CiĢýCa therapy support a valueĢýbased approach and help to meet budget requirements?

Our answer

CiĢýCa therapy may improve your CKRT cost structure and total cost of ownership compared to systemic anticoagulation:5,15

  • Fewer bleeding events, potentially resulting in a lower number of required blood transfusions5,16
  • Less filter clotting leads to fewer treatment interruptions, reducing the workload and increasing the plannability of tasks4,5,10,11
  • The smart CiĢýCa protocol enables efficient consumption of fluids by avoiding relevant predilution17,18

Think partner.
 Think CiĢýCa therapy.

Managing care is a complex task. You need to consider many different aspects Ģý from therapy optimization to processes and costs. We offer you a one-stop solution from a strong and reliable partner.

Your question

WhatĢýs the benefit for our hospital when switching to CiĢýCa therapy?

Our answer

Ģý can be your trusted one-stop business partner:

  • With our comprehensive CiĢýCa therapy portfolio of tailored products and services, we offer what you need for a reliable and effective CKRT4Ģý8,10,11from a single source.
  • As the world's leading provider of products and services for individuals with kidney diseases, we are able to provide the full range of support required for switching to CiĢýCa therapy as well as for daily operation.

Contact US

Close

Request a sales meet, demo or brochure by using this contact form


The information you provide will only be used to answer your query. For more information on how we process your Personal Data please read ourprivacy policy

This contact form is not intended to submit an adverse event related to medicinal products. To report an adverse event, please contact us atcorporate-drug-safety(at)freseniusmedicalcare.com.

Related content

No Results Found
PREVIOUS
    NEXT

    1Tsujimoto H et al. Cochrane Database Syst Rev. 2020; 12(12):CD012467

    2KDIGO Clinical Practice Guideline for Acute Kidney Injury., Kidney Int Suppl 2012; 2:1Ģý138

    3Bai M et al. Intensive Care Med 2015; 41:2098Ģý2110

    4Bianchi NA et al. Blood Purif 2020; 49:567Ģý575

    5Kalb R et al. Ther Apher Dial 2013; 17:202Ģý212

    6Morgera et al. Crit Care Med 2009;37:2018Ģý2024

    7Slowinski T et al. Crit Care 2015; 19:349

    8Link A et al. Crit Care 2012; 16:R97

    9Huguet M et al. Int J Artif Organs 2017; 40:676Ģý682

    10Hafner S et al. J Intensive Care 2015; 3:35

    11Houllé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35Ģý41

    12Hetzel GR et al. Nephrol Dial Transpl 2011; 26:232Ģý239

    13Zarbock A et al. JAMA 2020; 324:1629Ģý1639

    14Li L et al. Semin Dial 2021; 34:209Ģý217

    15Dalhuisen A et al. Neth J Crit Care 2017; 25:122Ģý127

    16Kindgen-Milles D et al. Curr Opin Crit Care 2018; 24:450Ģý454

    17Huang Z et al. Int J Artif Organs 2008, 31:525Ģý534

    18Nalesso F et al. J Clin Med 2020; 9:1529

    Share:

    Media center
    See all stories
    No Results Found
    See all stories
    PREVIOUS
      NEXT
      Events
      See all events
      No Results Found
      See all events
      PREVIOUS
        NEXT
        Contact
        Country websites

        All contact information

        Social Media